Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Wearables in Clinical Research: Data, Trends, and Challenges
Beyond the Endpoint
35 minutes 31 seconds
8 months ago
Wearables in Clinical Research: Data, Trends, and Challenges
Smartwatches, fitness trackers, and health data—how are wearables reshaping clinical research? In this episode, Dr. Marat Fudim joins us for an insightful discussion on how wearable technology is shaping the way we monitor health and conduct research. Topics include:
• Are wearables improving patient care or just tracking steps?
• How do researchers use wearable data in clinical trials?
•What are the biggest challenges in integrating this tech?
🎙️ Listen now and explore the possibilities of wearable health tech!
🔗 Access resources related to this episode https://dcri.org/blog/ep-4-wearables-clinical-research-data-trends-and-challenges
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
